AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

HOOKIPA Pharma to Present at Piper Jaffray 31st Annual Healthcare Conference

November 25, 2019

NEW YORK and VIENNA, Austria, Nov. 25, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will present and host one-on-one meetings at Piper Jaffray 31st Annual Healthcare Conference, taking place December 3-5, 2019 in New York:

-- Presentation: Tuesday, December 3, 2019 at 12:10 p.m. ET, Staten Island Track, Kennedy 1, 4th Floor

A live audio webcast of the presentation held at the Piper Jaffray Healthcare Conference will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration to augment and refresh immune responses. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA’s VaxWave®-based prophylactic cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT® based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus-positive cancers. The Phase 1/2 clinical trial initiation for HB-201 is still planned in 2019. The HB-202 IND filing is intended for the first half of 2020.

Find out more about HOOKIPA online at www.hookipapharma.com.

*Registered in Europe; Pending in the US.

For further information, please contact:

MediaNina Waibel Senior Director - Communications Nina.Waibel@HookipaPharma.com

InvestorsMatt BeckExecutive Director – Investor Relations Matthew.Beck@HookipaPharma.com

Media enquiries Sue Charles/ Ashley Tapp Instinctif Partners Hookipa@Instinctif.com +44 (0)20 7457 2020